Oncotarget

Corrections:

Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix

PDF  |  How to cite

Oncotarget. 2019; 10:4802-4802. https://doi.org/10.18632/oncotarget.27101

Metrics: PDF 595 views  |   ?  

Minakshi Mann1, Sachin Kumar1, Shyam S. Chauhan2, Neerja Bhatla3, Sunesh Kumar3, Sameer Bakhshi1, Ritu Gupta4, Ashok Sharma2 and Lalit Kumar1

1 Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
2 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
3 Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
4 Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Published: July 30, 2019

This article has been corrected: Dr. Ashok Sharma has been named as co-corresponding author on this paper, and has been moved from third place to second-to-last author in the listing.

Original article: Oncotarget. 2019; 10:4262–4275. DOI: https://doi.org/10.18632/oncotarget.27008.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27101